Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTMB versus Herceptin bioequivalence study in healthy male volunteers
NL-OMON35365Active, not recruiting
- Sponsor
- Synthon
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of trastuzumab in breast cancer and gastric cancer (GC) (3 arms), sponsored by Synthon. Primary endpoints: Bioequivalence pharmacokinetic profile and Safety and tolerability. Started Sep 2011; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON35365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35365.